Compugen's (CGEN) COM701 Could Make R&D Day A Catalyst - FBR

November 29, 2016 6:50 AM EST
Get Alerts CGEN Hot Sheet
Price: $4.60 -1.08%

Rating Summary:
    6 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade CGEN Now!
Join SI Premium – FREE

Get the Pulse of the Market with's Pulse Picks. Get your Free Trial here.

FBR Capital analyst, Vernon Bernadino, reiterated his Outperform rating on shares of Compugen (NASDAQ: CGEN) as COM701 emerges shifts from prediction to pipeline. CGEN-15029, the lead program identified by Compugen’s in silico predictive infrastructure platform technology, has approached a major milestone with the company’s plans to file an Investigational New Drug (IND) application in 2017 for COM701.

Compugen made a late-breaking abstract presentation at the annual meeting of the Society for Immunotherapy of Cancer (SITC) where CGEN-15029 was revealed as the internal designation for PVRIG, a novel immune checkpoint. The analyst, expects CGEN to discuss COM701 and the CGEN-15029 program in greater detail and further outline its clinical strategy during presentations at the upcoming R&D day in New York City on December 7, 2016.

No change to the price target of $14.

For an analyst ratings summary and ratings history on Compugen click here. For more ratings news on Compugen click here.

Shares of Compugen closed at $6.05 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Add Your Comment